Biomarkers for acute myeloid leukemia
AssigneesUniversite de Montreal, Universite Laval
InventorsBrian Thomas Wilhelm, Frederic Barabe
Life of this patent
Estimating the term…
Abstract
Methods for the diagnosis of leukemias, and more specifically AML, such as MLL-AF9 AML, in a subject, based on the assessment of the expression or activity of one or more of the genes listed in Tables 1 and 2 are disclosed. The use of antibodies or antigen-binding fragments thereof that bind to one or more of proteins showing preferential expression at the cell surface of AML leukemic cells for treating AML is also disclosed.
Claims3
A method for treating acute myeloid leukemia (AML) involving translocation of the mixed-lineage leukemia (MLL) gene in a subject, said method comprising administering to said subject an effective amount of a monoclonal antibody or an antigen-binding fragment thereof that binds to one or more of the following proteins:
- RET and CD70.
Dependencies are inferred from the claim text.